Hepatitis C Virus

Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy

Published in Medical Verdicts and Law Weekly, November 22nd, 2007

Human Genome Sciences, Inc. (NASDAQ:HGSI) announced the final results of a Phase 2 trial of the investigational drug, Albuferon(R) (albinterferon alfa-2b), in combination with ribavirin in patients with chronic hepatitis C who failed to respond to previous interferon-based therapy. The results were presented yesterday in Boston at the 58th AASLD Annual Meeting in Boston.

"The results of the Albuferon non-responder study demonstrated that Albuferon treatment at doses up to 1800 mcg every two weeks had an acceptable long-term safety profile and produced an overall sustained virologic response (SVR) rate of 17% in these patients," said David Nelson, M.D., Associate...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly

Source: Medical Verdicts and Law Weekly (2007-11-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry